A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Doravirine/islatravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 20 Mar 2024 This trial has been completed in Poland, according to European Clinical Trials Database
- 20 Mar 2024 This trial has been completed in Poland, according to European Clinical Trials Database
- 04 Mar 2024 Planned End Date changed from 7 Oct 2025 to 15 Oct 2027.